175 related articles for article (PubMed ID: 36290046)
1. Synthetic Flavonoid BrCl-Flav-An Alternative Solution to Combat ESKAPE Pathogens.
Moldovan CV; Savu M; Dussert E; Aboubacar H; Sarbu LG; Matiut S; Cudennec B; Krier F; Ravallec R; Birsa LM; Stefan M
Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290046
[TBL] [Abstract][Full Text] [Related]
2. The Antibacterial Synthetic Flavonoid BrCl-Flav Exhibits Important Anti-
Babii C; Savu M; Motrescu I; Birsa LM; Sarbu LG; Stefan M
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832912
[TBL] [Abstract][Full Text] [Related]
3. A novel synthetic flavonoid with potent antibacterial properties: In vitro activity and proposed mode of action.
Babii C; Mihalache G; Bahrin LG; Neagu AN; Gostin I; Mihai CT; Sârbu LG; Birsa LM; Stefan M
PLoS One; 2018; 13(4):e0194898. PubMed ID: 29617411
[TBL] [Abstract][Full Text] [Related]
4. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
[TBL] [Abstract][Full Text] [Related]
5. Repositioning of Benzodiazepine Drugs and Synergistic Effect with Ciprofloxacin Against ESKAPE Pathogens.
da Rosa TF; Serafin MB; Foletto VS; Franco LN; de Paula BR; Fuchs LB; Calegari L; Hörner R
Curr Microbiol; 2023 Apr; 80(5):160. PubMed ID: 37004588
[TBL] [Abstract][Full Text] [Related]
6. Membrane-active amino acid-coupled polyetheramine derivatives with high selectivity and broad-spectrum antibacterial activity.
Li H; Li Y; Wang Y; Liu L; Dong H; Satoh T
Acta Biomater; 2022 Apr; 142():136-148. PubMed ID: 35158080
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital.
Pandey R; Mishra SK; Shrestha A
Infect Drug Resist; 2021; 14():2201-2212. PubMed ID: 34163185
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antimicrobial activities of epigallocatechin gallate, myricetin, daidzein, gallic acid, epicatechin, 3-hydroxy-6-methoxyflavone and genistein combined with antibiotics against ESKAPE pathogens.
Buchmann D; Schultze N; Borchardt J; Böttcher I; Schaufler K; Guenther S
J Appl Microbiol; 2022 Feb; 132(2):949-963. PubMed ID: 34365707
[TBL] [Abstract][Full Text] [Related]
9. Human Salivary Protein Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens.
Du H; Puri S; McCall A; Norris HL; Russo T; Edgerton M
Front Cell Infect Microbiol; 2017; 7():41. PubMed ID: 28261570
[TBL] [Abstract][Full Text] [Related]
10. New Insights into the Antimicrobial Potential of
Savu M; Simo MK; Fopokam GX; Olaru SM; Cioanca O; Boyom FF; Stefan M
Microorganisms; 2022 Sep; 10(10):. PubMed ID: 36296219
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
[TBL] [Abstract][Full Text] [Related]
12. Non-Antimicrobial Drugs: Etodolac as a Possible Antimicrobial or Adjuvant Agent Against ESKAPE Pathogens.
Pereira SG; Domingues VS; Theriága J; Chasqueira MJ; Paixão P
Open Microbiol J; 2018; 12():288-296. PubMed ID: 30288184
[TBL] [Abstract][Full Text] [Related]
13. An Evaluation of the Antibacterial Properties of Tormentic Acid Congener and Extracts From
Chipenzi T; Baloyi G; Mudondo T; Sithole S; Fru Chi G; Mukanganyama S
Adv Pharmacol Pharm Sci; 2020; 2020():8848606. PubMed ID: 33225299
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity and proposed action mechanism of a new class of synthetic tricyclic flavonoids.
Babii C; Bahrin LG; Neagu AN; Gostin I; Mihasan M; Birsa LM; Stefan M
J Appl Microbiol; 2016 Mar; 120(3):630-7. PubMed ID: 26744255
[TBL] [Abstract][Full Text] [Related]
15. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
Tiwari V; Meena K; Tiwari M
Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
[TBL] [Abstract][Full Text] [Related]
16. Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.
Jadimurthy R; Mayegowda SB; Nayak SC; Mohan CD; Rangappa KS
Biotechnol Rep (Amst); 2022 Jun; 34():e00728. PubMed ID: 35686013
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of medicinal plants against ESKAPE: An update.
Bhatia P; Sharma A; George AJ; Anvitha D; Kumar P; Dwivedi VP; Chandra NS
Heliyon; 2021 Feb; 7(2):e06310. PubMed ID: 33718642
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activities of and biofilm removal by Ablysin, an endogenous lysozyme-like protein originated from Acinetobacter baumannii 1656-2.
Kim S; Jin JS; Lee DW; Kim J
J Glob Antimicrob Resist; 2020 Dec; 23():297-302. PubMed ID: 33045439
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antibacterial effect of apigenin with β-lactam antibiotics and modulation of bacterial resistance by a possible membrane effect against methicillin resistant Staphylococcus aureus.
Akilandeswari K; Ruckmani K
Cell Mol Biol (Noisy-le-grand); 2016 Dec; 62(14):74-82. PubMed ID: 28145860
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characterization of Gene-Mediated Resistance and Susceptibility of ESKAPE Clinical Isolates to
Zalegh I; Bourhia M; Zerouali K; Katfy K; Nayme K; Khallouki F; Benzaarate I; Mohammad Salamatullah A; Alzahrani A; Nafidi HA; Akssira M; Ait Mhand R
Evid Based Complement Alternat Med; 2022; 2022():7467279. PubMed ID: 36204117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
